Rational Pharmacotherapy in Cardiology

Advanced search


Full Text:


Background. The prevalence of hypercholesterolemia (HCE) is quite high in the Russian Federation (RF), and it is associated with clinical consequences and with potential economic impact. Impact includes not only cost of its correction, but also the cost of treatment of diseases and complications, as well as the deficiency of the gross domestic product (GDP).

Aim. Evaluation of economic impact due to HCE in the Russian population, including direct expenditures of the Health Care System as well as nondirect impact in common economy.

Material and methods. Prevalence of HCE in the RF was identified based on local published studies. Local statistical data (2016) on cardio-vascular diseases (CVDs), including Ischemic Heart Disease (IHD), Myocardial Infarction and cerebral-vascular disease were included in the analysis. Population Attributive Risk (PAR) of HCE in CVDs has been extrapolated on all Russian population. Official statistics, parameters of Govern Guarantees Program of Free Medical Aid were used for modelling of direct and non-direct components of economic impact. Total amount of premature deaths with calculation of years of potential life lost until life expectation at 72 years was calculated. Economic impact due to premature CVDs mortality in economic activity age with consideration on ratio of employment have included GDP lost. Calculation of GDP lost also included monetary impact based on number of disability CVDs patients multiplied on GDP per capita in disability group.

Results. Visits to policlinics of patients with CVDs and HCE had a first place among all calls for medical aid. In the same time, hospitalization required in higher expenditures (outpatients cost treatment expenditures were 2.43 billion RUR, in-patients treatment – 18.21 billion RUR). IHD with HCE was most expensive for direct expenditures in comparison with other CVD groups: more than 28.9 billion RUR per year, and with direct non-medical expenditures of 29.3 billion RUR in total. Years of potential life lost in economic active age were one million in total, 1.29 trillion RUR per year mostly due to indirect expenditures due to premature deaths in economy activity age (99% of impact). Total Economic impact due to HCE in the Russian population for all HCE are estimated as 1.295 trillion RUR.

Conclusion. Total economic impact due to HCE in the RF is 1.5% of GDP (2016), 1.295 trillion RUR. Direct expenditures included Health Care System expenses; disability covering had 2.3% only. Main part of impact is economic lost due to premature mortality and decrease of labor productivity. HCE patients control at target levels with help of healthy lifestyle and adequate pharmaceutical therapy can decrease economic impact. 

About the Authors

A. V. Kontsevaya
National Medical Research Center for Preventive Medicine
Russian Federation

MD, PhD, Deputy Director for Scientific and Analytical Work,

Petroverigsky per., 10, Moscow, 101990

Yu. A. Balanova
National Medical Research Center for Preventive Medicine
Russian Federation

MD, PhD, Leading Researcher, Laboratory of Economic Analysis of Epidemiological Research and Preventive Technologies, Department of Epidemiology of Chronic Non-Communicable Diseases,

Petroverigsky per., 10, Moscow, 101990

A. E. Imaeva
National Medical Research Center for Preventive Medicine
Russian Federation

MD, PhD, Senior Researcher, Department of Epidemiology of Chronic Non-Communicable Diseases,

Petroverigsky per., 10, Moscow, 101990

M. B. Khudyakov
National Medical Research Center for Preventive Medicine
Russian Federation

Leading Engineer, Laboratory of Economic Analysis of Epidemiological Research and Preventive Technologies, Department of Epidemiology of Chronic Non-Communicable Diseases,

Petroverigsky per., 10, Moscow, 101990

O. I. Karpov
Public Company “Sanofi Russia”
Russian Federation

MD, PhD, Professor, Head of Health Economics and Outcomes Research Group,

Tverskaya ul. 22, Moscow, 125009

O. M. Drapkina
National Medical Research Center for Preventive Medicine
Russian Federation

MD, PhD, Professor, Corresponding Member of the Russian Academy of Science, Director,

Petroverigsky per., 10, Moscow, 101990


1. Oganov R.G., Kontsevaya A.V., Kalinina A.M. State Economic Burden of Cardiovascular Diseases in the Russian Federation. Cardiovascular Therapy and Prevention. 2011;10(4):4-9. (In Russ.) [Оганов Р.Г., Концевая А.В., Калинина А.М. Экономический ущерб от сердечно-сосудистых заболеваний в Российской Федерации. Кардиоваскулярная Терапия и Профилактика. 2011;10(4):4-9].

2. Mahmood S.S., Levy D., Vasan R.S. et al. The Framingham Heart Study and the epidemiology of cardiovascular disease: A historical perspective. Lancet. 2014;383:999-1008. doi 10.1016/S0140-6736(13)61752-3.

3. Yusuf, S., Hawken, S., Ôunpuu, S., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937-52. doi: 10.1016/S0140-6736(04)17018-9.

4. Dragomir A., Côté R., White M. et al. Relationship between Adherence Level to Statins, Clinical Issues and Health-Care Costs in Real-Life Clinical Setting. Value in Health. 2010;13(1):87-94. doi: 10.1111/j.1524-4733.2009.00583.x.

5. Virtanen M., Ervasti J., Mittendorfer-Rutz E., Lallukka T. et al. Work disability before and after a major cardiovascular event: A ten-year study using nationwide medical and insurance registers. Scientific Reports. 2017;7(1):1142. doi: 10.1038/s41598-017-01216-2.

6. National Institute for Health and Clinical Excellence (NICE). Statins for the prevention of cardiovascular events. [cited Jun 15, 2018]. Available from: NICE_TA094guidance.pdf.

7. Filippov E.V., Balanova Yu.A. Dyslipidemia and its relationship with chronic non-communicable diseases (according to the MERIDIAN-RO study). Medicinskij Sovet. 2015;12:104-10. (In Russ.) [Филиппов Е.В., Баланова Ю.А. Дислипидемии и их связь с хроническими неинфекционными заболеваниями (по данным исследования МЕРИДИАН-РО). Медицинский Совет. 2015;12:104-10].

8. Metelskaya V.A., Shalnova S.A., Deev A.D. Analysis of atherogenic dyslipidemias prevalence among population of Russian Federation (results of the ESSE-RF Study). Profilakticheskaya Meditsina. 2016;19(1):15-23. (In Russ.) [Метельская В.А., Шальнова С.А., Деев А.Д. и др. Анализ распространенности показателей, характеризующих атерогенность спектра липопротеинов, у жителей Российской Федерации (по данным исследования ЭССЕ-РФ). Профилактическая Медицина. 2016;19(1):15-23]. doi: 10.17116/profmed201619115-23.

9. Balanova Yu.A., Deev A.D., Ivanov V.М. The results of the first stage of the epidemiological situation monitoring of arterial hypertension in the Russian Federation (2003-2004), carried out in the framework of the federal target program "Prevention and treatment of hypertension in the Russian Federation". Moscow: Meditsina dlya vas; 2005. (In Russ.) [Баланова Ю.А., Деев А.Д., Иванов В.М., др. Результаты первого этапа мониторинга эпидемиологической ситуации по артериальной гипертонии в РФ (2003-2004), проведенного в рамках Федеральной целевой программы «Профилактика и лечение артериальной гипертонии в РФ». Москва: Медицина для вас; 2005].

10. Shalnova S.A., Deev A.D., Metelskaya V.A. et al. Awareness and treatment specifics of statin therapy in persons with various cardiovascular risk: the study ESSE-RF. Cardiovascular Therapy and Prevention. 2016;15(4):29-37. (In Russ.) [Шальнова С.А., Деев А.Д. Метельская В.А. и др. Информированность и особенности терапии статинами у лиц с различным сердечно-сосудистым риском: исследование ЭССЕ-РФ. Кардиоваскулярная Терапия и Профилактика. 2016;15(4):29-37]. doi: 10.15829/1728-8800-2016-4-29-37.

11. Hallberg S., Gandra S.R., Fox K.M. et al. Healthcare costs associated with cardiovascular events in patients with hyperlipidemia or prior cardiovascular events: estimates from Swedish populationbased register data. The European Journal of Health Economics. 2016;17(5):591-601. doi: 10.1007/s10198-015-0702-0.

12. Fox K.M., Wang L., Gandra S. R. et al. Clinical and economic burden associated with cardiovascular events among patients with hyperlipidemia: a retrospective cohort study. BMC cardiovascular disorders. 2016;16(1):13. doi: 10.1186/s12872-016-0190-x.

13. Kontsevaya A.V., Drapkina O.M., Balanova Y.A. et al. Economic Burden of Cardiovascular Diseases in the Russian Federation in 2016. Rational Pharmacotherapy in Cardiology. 2018;14(2):156-66. (In Russ.) [Концевая А.В., Драпкина О.М., Баланова Ю.А. и соавт. Экономический ущерб от сердечно-сосудистых заболеваний в Российской Федерации в 2016 году. Рациональная Фармакотерапия в Кардиологии. 2018;14(2):156-66]. doi: 10.20996/1819-6446-2018-14-2-156-166.

14. Government Decision № 1382 of 19 December 2015 «On the Programme of State guarantees for providing citizens of the Russian Federation with free medical care for 2016» (In Russ.) [Постановление Правительства РФ от 19 декабря 2015 г. № 1382 «О Программе государственных гарантий бесплатного оказания гражданам медицинской помощи на 2016»].

15. The demographic yearbook of Russia. Statistical handbook. Moscow: Rosstat; 2017. (In Russ.) [Демографический ежегодник России (2017). Статистический сборник. М.: Росстат; 2017].

16. Government Decision N247 of 18.03.2015 “On the approval of the indexation coefficient from 01/04/2015 of social pensions”. [cited Jun 15, 2018]. Available from: http://base. (In Russ.) [Постановление Правительства РФ от 18.03.2015 N 247 «Об утверждении коэффициента индексации с 01.04.2015 социальных пенсий». [цитировано 15.06.2018]. Доступно на:].

17. WHO Mortality Database [cited Jun 15, 2018]. Available from: mortality_data/en/.

18. Russian database on fertility and mortality. [cited Jun 15, 2018]. Available from: (In Russ.) [Российская база данных по рождаемости и смертности (РосБРиС). [цитировано 15.06.2018]. Доступно на:].

19. Statistical Bulletin Labor and Employment in Russia. Moscow: Rosstat; 2017. (In Russ.) [Труд и занятость в России (2017). Статистический сборник. Москва: Росстат; 2017].

20. Hall P.S., Edlin R., Kharroubi S. et al. Expected net present value of sample information: From burden to investment. Medical Decision Making. 2012;32(3):E11-E21. doi: 10.1177/0272989X 12443010.

21. Government Decision №192/323н/45н/113 of 10 April 2012 "On the approval of the methodology for calculating economic losses from mortality, morbidity and disability of the population" №192/323н/45н/113 «On the approval of the Methodology for calculating economic losses from mortality, morbidity and disability of the population». [cited Mar 02, 2018]. Available from: (In Russ.) [Приказ МЭР РФ, МЗ и СР РФ, Минфина РФ и Федеральной службы государственной статистики от 10 апреля 2012 г. № 192/323н/45н/113 «Об утверждении Методологии расчета экономических потерь от смертности, заболеваемости и инвалидизации населения» [цитировано 02.03.2018]. Доступно на:].

22. Gutierrez J., Ramirez G., Rundek T, et al. Statin Therapy in the Prevention of Recurrent Cardiovascular Events. Cochrane Database Syst Rev. 2013(1):909-19. doi: 10.1001/archinternmed.2012.2145.

23. Taylor F., Ward K., Moore T. H. et al. Statins for the primary prevention of cardiovascular disease ( Review ). Cochrane Rev. 2013(1):1. doi: 10.1002/14651858.CD004816.pub4.

24. Conly J., Clement F., Tonelli M., et al. Cost-effectiveness of the use of low-and high-potency statins in people at low cardiovascular risk. CMAJ. 2011;183(16):1189-202. doi: 10.1503/cmaj.101281.

25. Ford E.S., Capewell S. Trends in Total and Low-Density Lipoprotein Cholesterol among U.S. Adults: Contributions of Changes in Dietary Fat Intake and Use of Cholesterol-Lowering Medications. PLoS One. 2013;8(5):1-8. doi: 10.1371/journal.pone.0065228.

26. Guzman-Castillo M., Ahmed R., Hawkins N. et al. The contribution of primary prevention medication and dietary change in coronary mortality reduction in England between 2000 and 2007: a modelling study. BMJ Open. 2015;5(1):e006070. doi: 10.1136/bmjopen-2014-006070.

27. Wang W., Zhang B. Statins for the prevention of stroke: A meta-analysis of randomized controlled trials. PLoS One. 2014;9(3):e92388. doi: 10.1371/journal.pone.0092388.

28. Barquera S., Pedroza-Tobías A., Medina C. et al. Global Overview of the Epidemiology of Atherosclerotic Cardiovascular Disease. Archives of Medical Research. 2015;46(5):328-38. doi: 10.1016/j.arcmed.2015.06.006.

29. Voevoda M.I., Kovalkova N.A., Ragino Yu.I. Prevalence of metabolic syndrome in 25-45-year-old Novosibirsk dwellers. Terapevticheskij Arkhiv. 2016;88(10):51-6. (In Russ.) [Воевода, М. И., Ковалькова, Н. А., Рагино, Ю. И., Травникова, Н. Ю., Денисова Д.В. Распространенность метаболического синдрома у жителей Новосибирска в возрасте от 25 до 45 лет. Терапевтический архив. 2016;88(10):51-6]. doi: 10.17116/terarkh2016881051-56.

30. Zvolinskaya E.Yu., Alexandrov A.A., Deev A.D. Epidemiological Situation With Main Risk Factors of Cardio-Vascular Diseases Among Young Adults in Russian Federation. Kardiologiia. 2015;55:1263-69. (In Russ.) [Зволинская Е.Ю., Александров А.А., Деев А.Д. и др. Эпидемиологическая ситуация по основным факторам риска развития сердечно-сосудистых заболеваний в Российской Федерации среди лиц молодого возраста. Кардиология. 2015;55:1263-69]. doi: 10.18565/cardio.2015.12.63-69.

31. Akhmedzhanov N.M., Nebieridze D.V., Safaryan A.S. et al. Analysis of hypercholesterolemia prevalence in the outpatient practice (according to the ARGO study): Part I. Ration Pharmacother Cardiol. 2015;11(3):253-60. (In Russ.) [Ахмеджанов Н.М., Небиеридзе Д.В., Сафарян А.С. и др. Анализ распространенности гиперхолестеринемии в условиях амбулаторной практики (по данным исследования АРГО): Часть I. Рациональная Фармакотерапия в Кардиологии. 2015;11(3):253-60]. doi: 10.20996/1819-6446-2015-11-3-253-260.

32. Rosinger A. Carroll M. D., Lacher D., et al. Trends in Total Cholesterol, Triglycerides, and Low-Density Lipoprotein in US Adults, 1999-2014. JAMA Cardiol. 2016;2(3):339-41. doi: 10.1001/jamacardio.2016.4396.

33. Eriksson M., Forslund A.S., Jansson J.H., et al. Greater decreases in cholesterol levels among individuals with high cardiovascular risk than among the general population: The northern Sweden MONICA study 1994 to 2014. Eur Heart J. 2016;37(25):1985-92. doi: 10.1093/eurheartj/ehw052.

34. Chan T., Dabin B., Hyun K.,et al. Falling cholesterol trend at acute coronary syndrome presentation is strongly related to statin use for secondary prevention. Elsevier Ireland Ltd; 2016;212:192-7. doi: 10.1016/j.ijcard.2016.03.038.

35. McAloon C.J., Boylan L.M., Hamborg T., et al. The changing face of cardiovascular disease 2000-2012: An analysis of the world health organisation global health estimates data. Int J Cardiol. 2016;224:256-64. doi: 10.1016/j.ijcard.2016.09.026.

36. Jousilahti P, Vartiainen E, Pekkanen J et al. Serum Cholesterol Distribution and Coronary Heart Disease Risk : Observations and Predictions Among Middle-aged Population in Eastern Finland. Circulation. 1998;97(11):1087-94.

37. doi: 10.1161/01.CIR.97.11.1087. 37. Norman R., Bradshaw D., Steyn K., et al. Estimating the burden of disease attributable to high cholesterol in South Africa in 2000. S Afr Med J. 2007;97(8):708-15.

38. Capewell S., Morrison C.E., McMurray J.J. Contribution of modern cardiovascular treatment and risk factor changes to the decline in coronary heart disease mortality in Scotland between 1975 and 1994. Heart. 1999;81:380-6. doi: 10.1136/hrt.81.4.380.

39. Iversen A., Jensen J.S., Scharling H. et al. Hypercholesterolaemia and risk of coronary heart disease in the elderly: Impact of age. The Copenhagen City Heart Study. Eur J Intern Med. 2009;20(2):139-44. doi: 10.1016/j.ejim.2008.06.003.

40. Blackburn D.F., Dobson R.T., Blackburn J.L., et al. Cardiovascular morbidity associated with nonadherence to statin therapy. Pharmacotherapy. 2005;25(8):1035-43. doi: 10.1592/phco.2005. 25.8.1035.

41. Foody J.M., Joyce A.T., Rudolph A.E., et al. Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin therapy: A large database analysis of managed care plans in the United States. Clin Ther. 2008;30(1):195-205. doi: 10.1016/j.clinthera.2008.01.003.

42. Wei L., Wang J., Thompson P., et al. Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study. Heart. 2002;88(3):229-33. doi: 10.1136/heart. 88.3.229.

43. Punekar R.S., Fox K.M., Richhariya A., et al. Burden of First and Recurrent Cardiovascular Events among Patients with Hyperlipidemia. Clin Cardiol. 2015;38(8):483-91. doi: 10.1002/clc.22428.

44. Gouveia M., Borges M., Augusto M. et al. Cost and Burden Of Hypercholesterolemia In Portugal. Value Heal. 2014;17(7):A339. doi: 10.1016/j.jval.2014.08.668.

45. Müller-Nordhorn J., Englert H., Wegscheider K., et al. Productivity loss as a major component of disease-related costs in patients with hypercholesterolemia in Germany. Clin Res Cardiol. 2008;97(3):152-9. doi: 10.1007/s00392-007-0602-0.

For citation:

Kontsevaya A.V., Balanova Y.A., Imaeva A.E., Khudyakov M.B., Karpov O.I., Drapkina O.M. ECONOMIC BURDEN OF HYPERCHOLESTEROLEMIA IN THE RUSSIAN FEDERATION. Rational Pharmacotherapy in Cardiology. 2018;14(3):393-401. (In Russ.)

Views: 215

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)